share_log

Apollomics | EFFECT: Others

Apollomics | EFFECT: Others

Apollomics | EFFECT:其他
美股SEC公告 ·  04/25 06:05

Moomoo AI 已提取核心訊息

The United States Securities and Exchange Commission (SEC) has declared a Form F-3 filing by Apollomics Inc. effective as of April 24, 2024, at 5:00 PM. This notice of effectiveness allows Apollomics, a biopharmaceutical company, to potentially offer and sell securities in the future. The Form F-3, associated with file number 333-278430, is a registration statement used by foreign private issuers to register securities offerings in the U.S. market. The effectiveness of this filing is a regulatory step that enables Apollomics to access U.S. capital markets for potential fundraising activities.
The United States Securities and Exchange Commission (SEC) has declared a Form F-3 filing by Apollomics Inc. effective as of April 24, 2024, at 5:00 PM. This notice of effectiveness allows Apollomics, a biopharmaceutical company, to potentially offer and sell securities in the future. The Form F-3, associated with file number 333-278430, is a registration statement used by foreign private issuers to register securities offerings in the U.S. market. The effectiveness of this filing is a regulatory step that enables Apollomics to access U.S. capital markets for potential fundraising activities.
美國證券交易委員會(SEC)已宣佈Apollomics Inc.提交的F-3表格自2024年4月24日下午5點起生效。該生效通知使生物製藥公司Apollomics有可能在未來發行和出售證券。文件編號爲333-278430的F-3表格是外國私人發行人用來在美國市場註冊證券發行的註冊聲明。該申請的有效性是一項監管措施,使Apollomics能夠進入美國資本市場進行潛在的籌款活動。
美國證券交易委員會(SEC)已宣佈Apollomics Inc.提交的F-3表格自2024年4月24日下午5點起生效。該生效通知使生物製藥公司Apollomics有可能在未來發行和出售證券。文件編號爲333-278430的F-3表格是外國私人發行人用來在美國市場註冊證券發行的註冊聲明。該申請的有效性是一項監管措施,使Apollomics能夠進入美國資本市場進行潛在的籌款活動。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息